TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25066269

Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg, intravenous) with mFOLFOX6
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low-dose linifanib (7.5 mg) with mFOLFOX6
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: High-dose linifanib (12.5 mg) with mFOLFOX6
Number of subjects: 148
Study: 22199189

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20845988

Group type: EXPERIMENTAL
Intervention: Plasma cell-free DNA
Number of subjects: 360
Study: 18057338

Group type: EXPERIMENTAL
Intervention: Tesamorelin (2 mg daily subcutaneous injection for 26 weeks)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 412
Study: 15638875

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12105323

Group type: EXPERIMENTAL
Intervention: Topiramate (400 mg/d or maximum tolerated dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10427867

Group type: EXPERIMENTAL
Intervention: Oxygen indices (P(A‐a)O2, PaO2/FiO2, PaO2/PAO2, P(A‐a)O2/PaO2) after FiO2 modifications
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FiO2‐required formula to obtain desired PaO2
Number of subjects: 50
Study: 1391977

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 92

Group type: COMPARATOR
Intervention: No hormone treatment (Control)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Tamoxifen (in premenopausal women)
Number of subjects: 92
Study: 3999081

Group type: EXPERIMENTAL
Intervention: Diumide‐K Continus tablets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lasikal tablets
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lasix and Slow‐K tablets
Number of subjects: 30
Study: 30381244

Group type: EXPERIMENTAL
Intervention: Blue-enriched light (high intensity of ca. 1000 lx, short duration: <1 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Red-enriched light
Number of subjects: 0
Study: 29364579

Group type: EXPERIMENTAL
Intervention: Nutritional protein-rich drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 0
Study: 26525831

Group type: EXPERIMENTAL
Intervention: High oxygen concentration (100%)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mild oxygen concentration (60%)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low oxygen concentration (40%)
Number of subjects: 52
Study: 26696093

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects (control group) cultured with GM-CSF or M-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study: 24013592

Group type: EXPERIMENTAL
Intervention: Neuronal representations of novel rewards constructed by invoking multiple independent memories in hippocampus and medial prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging repetition suppression
Number of subjects: 0
Study: 20501982

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (n = 20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (n = 15)
Number of subjects: 35
Study: 18309618

Group type: EXPERIMENTAL
Intervention: Chairside airborne particle abrasion with 50-microm Al2O2 + Alloy Primer (Kuraray)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion with 50-microm Al2O3 + Cesead II Opaque Primer (Kuraray)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion with 50-microm Al2O3 + Silano-Pen + silane coupling agent (Bredent)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laboratory tribochemical silica coating (110-microm Al2O3 + 110-microm SiOx) (Rocatec) + silane coupling agent (ESPE-Sil)
Number of subjects: 40
Study: 16543099

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 12655908

Group type: EXPERIMENTAL
Intervention: Trazodone or nefazodone
Number of subjects: 147

Group type: COMPARATOR
Intervention: Other antidepressant drugs
Number of subjects: 147

Group type: COMPARATOR
Intervention: Nonteratogenic drugs
Number of subjects: 147
Study: 10984014

Group type: EXPERIMENTAL
Intervention: Erdosteine syrup 3.5%
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Erdosteine sachets 225 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (for syrup 3.5%)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (for sachets 225 mg)
Number of subjects: 200
Study: 9475311

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid aspartate levels in patients with infantile spasms
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid glutamate levels in patients with infantile spasms
Number of subjects: 13
Study: 8014172

Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3236320

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28892237

Group type: EXPERIMENTAL
Intervention: Group psychoeducation with relaxation
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Emergency cesarean delivery
Number of subjects: 250

Group type: COMPARATOR
Intervention: Partners of women with severe FOC
Number of subjects: 250
Study: 28277692

Group type: EXPERIMENTAL
Intervention: Decision-making with a random device for allocation of rewards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decision-making without a random device for allocation of rewards
Number of subjects: 0
Study: 23774275

Group type: EXPERIMENTAL
Intervention: Plant-derived alpha-linolenic acid (ALA) 2g/day
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 400mg/day
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2425
Study: 23321021

Group type: EXPERIMENTAL
Intervention: Teacher professional development evaluation
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Teacher implementation
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Student reception
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Teacher satisfaction with teaching the curriculum
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Teacher perception of amount of student work
Number of subjects: 562
Study: 20005744

Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (average effect site concentration 1.99 +/- 0.02 ng/mL) with epidural analgesia with 0.5% ropivacaine started at the beginning of anesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: High-dose remifentanil (average effect-site concentration 5.61 +/- 0.84 ng/mL) with epidural analgesia started and at the end of surgery
Number of subjects: 38
Study: 18155990

Group type: EXPERIMENTAL
Intervention: Diacylglycerol oil
Number of subjects: 312

Group type: COMPARATOR
Intervention: Triacylglycerol oil
Number of subjects: 312
Study: 16889593

Group type: EXPERIMENTAL
Intervention: Bright light therapy of 10,000 lux/wide spectrum for 3 weeks
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo intervention (dark sunglasses during sessions)
Number of subjects: 1
Study: 12962946

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 11304971

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 50
Study: 8640980

Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 6
Study: 1602361

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acyclovir suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foscarnet maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chronic antiviral therapy
Number of subjects: 0
Study: 6596056

Group type: EXPERIMENTAL
Intervention: Increased sodium intake (70-200 mmol/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased sodium intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium interaction with sodium
Number of subjects: 0
Study: 30361322

Group type: EXPERIMENTAL
Intervention: Allen Carr's Easyway to Stop Smoking (AC)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Quit.ie
Number of subjects: 300
Study: 29509579

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 89
Study: 26038818

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT, n = 15)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined Training (CT, n = 32)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control Group (CG, n = 18)
Number of subjects: 65
Study: 24577230

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at three doses (200 mg, 400 mg, 800 mg/day) for 12 weeks
Number of subjects: 171

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 171
Study: 22118780

Group type: EXPERIMENTAL
Intervention: Hot packs (15min at 60°C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) (15min at 1Mhz)
Number of subjects: 20
Study: 20518807

Group type: EXPERIMENTAL
Intervention: Taranabant 0.5 mg
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Taranabant 1 mg
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Taranabant 2 mg
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Taranabant (all doses)
Number of subjects: 623
Study: 17952847

Group type: EXPERIMENTAL
Intervention: Common single-nucleotide polymorphisms (SNPs) in seven genes involved in HDL metabolism
Number of subjects: 0

Group type: COMPARATOR
Intervention: 660 polymorphisms in eight genes not involved in HDL metabolism
Number of subjects: 0
Study: 15817602

Group type: EXPERIMENTAL
Intervention: FEC followed by high dose therapy (HDT) consisting of cyclophosphamide, thiotepa, and carboplatin with stem cell rescue
Number of subjects: 281

Group type: COMPARATOR
Intervention: Conventional treatment (5-fluorouracil, epirubicin, and cyclophosphamide - FEC for six cycles)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: FEC followed by HDT
Number of subjects: 281

Group type: COMPARATOR
Intervention: Conventional FEC
Number of subjects: 281
Study: 12219032

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin at a rate of at least 1.5 microU/kg/min to maintain serum glucose levels between 100 to 140 mg/dL
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no insulin treatment)
Number of subjects: 18
Study: 10367025

Group type: EXPERIMENTAL
Intervention: Calcium carbonate at 300 mg load
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Calcium citrate at 300 mg load
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Calcium carbonate at 1000 mg load
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Calcium citrate at 1000 mg load
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcium carbonate vs. calcium citrate at high load
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcium carbonate vs. calcium citrate at low load
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcium carbonate vs. calcium citrate at 1000 mg load (urinary increment method)
Number of subjects: 37
Study: 7786951

Group type: EXPERIMENTAL
Intervention: Redesigned cervical smear request form allowing direct notification by mail
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard notification process (control group)
Number of subjects: 42
Study: 2187013

Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 180
Study: 924791

Group type: EXPERIMENTAL
Intervention: Danitracene 1-3 x 0.5 mg/day for 1-3-6 months
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Danitracene 1-3 x 0.5 mg/day
Number of subjects: 75
Study: 31255452

Group type: EXPERIMENTAL
Intervention: XINSORB bioresorbable sirolimus-eluting scaffold
Number of subjects: 1193

Group type: COMPARATOR
Intervention: sirolimus-eluting stent (SES)
Number of subjects: 1193
Study: 29088439

Group type: EXPERIMENTAL
Intervention: AutoPulse
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: LUCAS
Number of subjects: 374

Group type: COMPARATOR
Intervention: Manual CC
Number of subjects: 374
Study: 25743937

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg) with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg)
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 23902779

Group type: EXPERIMENTAL
Intervention: Folic acid alone
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B-12 combination
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 alone
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 21757938

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 19371315

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg b.i.d. for 7 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Carbamazepine titrated up to 200 mg b.i.d. over 20 days
Number of subjects: 46
Study: 17040577

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum copper levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum iron levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum selenium levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIC, serum copper, iron and selenium
Number of subjects: 0
Study: 12571674

Group type: EXPERIMENTAL
Intervention: Test diet (high in protein, 27% of energy from protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet (16% of energy from protein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study: 11093555

Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament (SWM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vibration perception thresholds (VPT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Screening plus treatment for those with previous ulcers
Number of subjects: 10
Study: 9181277

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2 micrograms/kg/min for two hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study: 1327049

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 micrograms twice daily for 5 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inhaled PAF (total cumulative dose of 500 micrograms)
Number of subjects: 9
Study: 3908329

Group type: EXPERIMENTAL
Intervention: Disopyramide (7 mg/kg per day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 26
Study: 30514108

Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sheet of exercises (n=45; active comparator)
Number of subjects: 90
Study: 28920550

Group type: EXPERIMENTAL
Intervention: Physical Activity Monitor (PAM) group, n=38
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Assistance required in STS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Independent in STS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall mobility improvement
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: STS performance
Number of subjects: 61

Group type: COMPARATOR
Intervention: Group allocation effect on outcomes
Number of subjects: 61
Study: 27161860

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone therapy for 12 weeks
Number of subjects: 148
Study: 25128076

Group type: EXPERIMENTAL
Intervention: FORTA intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 114
Study: 22432104

Group type: EXPERIMENTAL
Intervention: Lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, then 20 μg)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Lixisenatide 1-step (10 μg for 2 weeks, then 20 μg)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo (combined 2-step and 1-step)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Lixisenatide (both regimens)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 20562069

Group type: EXPERIMENTAL
Intervention: Elixir DESyne Novolimus Eluting Coronary Stent System (NES)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Endeavor zotarolimus eluting stent (ZES)
Number of subjects: 210
Study: 17621495

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: ADHD children off methylphenidate
Number of subjects: 15
Study: 15621328

Group type: EXPERIMENTAL
Intervention: Tester for quantitative measurement of anterior ankle joint laxity
Number of subjects: 24
Study: 12232843

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no filgrastim)
Number of subjects: 36
Study: 10194055

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 217

Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 217
Study: 7552133

Group type: EXPERIMENTAL
Intervention: Disposable instruments
Number of subjects: 158

Group type: COMPARATOR
Intervention: Reusable instruments
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 2109927

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion (5 ng/kg/min for 72 hours)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion
Number of subjects: 27
Study: 7010886

Group type: EXPERIMENTAL
Intervention: Timolol 0.25% and 0.5%
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pilocarpine 1%, 2%, or 4%
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg x 3) added if IOP uncontrolled
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Timolol once a day administration
Number of subjects: 58
Study: 31734151

Group type: EXPERIMENTAL
Intervention: Foot massage therapy (10-minute sessions, twice during one day, within 30 minutes after opioid pain medication)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo control (no foot massage)
Number of subjects: 31
Study: 30680852

Group type: EXPERIMENTAL
Intervention: 24 weeks of varenicline (extended treatment)
Number of subjects: 207

Group type: COMPARATOR
Intervention: 12 weeks of varenicline plus 12 weeks of placebo (standard treatment)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 207
Study: 28614266

Group type: EXPERIMENTAL
Intervention: Numerical information presentation
Number of subjects: 515

Group type: COMPARATOR
Intervention: Disordered information presentation
Number of subjects: 515

Group type: COMPARATOR
Intervention: Star rating presentation
Number of subjects: 515

Group type: COMPARATOR
Intervention: Other aspects of PRCPI
Number of subjects: 515
Study: 26360979

Group type: EXPERIMENTAL
Intervention: Fasudil (2.67 mmol/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Papaverine (1.0 mmol/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Verapamil-nitroglycerin (30 μmol/L each)
Number of subjects: 30
Study: 24151272

Group type: EXPERIMENTAL
Intervention: AlloMatrix bone graft
Number of subjects: 50

Group type: COMPARATOR
Intervention: No graft
Number of subjects: 50
Study: 21377153

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Urinary hCG
Number of subjects: 96

Group type: COMPARATOR
Intervention: Natural cycle
Number of subjects: 96
Study: 19688314

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Xuezhikang
Number of subjects: 88

Group type: COMPARATOR
Intervention: Antihypertensive drugs (ATH group)
Number of subjects: 88
Study: 18823205

Group type: EXPERIMENTAL
Intervention: Cuing of specific response subsets grouped by hand or by finger equivalence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random baseline condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task switching
Number of subjects: 0
Study: 16268244

Group type: EXPERIMENTAL
Intervention: Specialist physicians
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Male physicians
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Early- and late-career physicians
Number of subjects: 2183

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 2183
Study: 11904526

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel and ASA
Number of subjects: 60
Study: 10559611

Group type: EXPERIMENTAL
Intervention: Oral bropirimine (3 g/day for 3 consecutive days with a 4-day drug-free interval for up to 1 year)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravesical BCG (weekly for 2 x 6 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral bropirimine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravesical BCG
Number of subjects: 55
Study: 7797904

Group type: EXPERIMENTAL
Intervention: rBPI23
Number of subjects: 8